Temporal trends in anticholinergic medication prescription in older people: Repeated crosssectional analysis of population prescribing data

Age and Ageing

Volumn 43, Issue 4, 2014, Pages 515-521

  Sumukadas, Deepa ^a   McMurdo, Marion E T ^a   Mangoni, Arduino A ^b   Guthrie, Bruce ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Anticholinergic medication; Older people; Prescription

Indexed keywords

AMITRIPTYLINE; ATROPINE; BENZATROPINE; CETIRIZINE; CHLORPHENIRAMINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLEMASTINE; CYPROHEPTADINE; DICYCLOVERINE; DOSULEPIN; FLUPHENAZINE; LOFEPRAMINE; LOPERAMIDE; LORATADINE; METOCLOPRAMIDE; MIRTAZAPINE; OXYBUTYNIN; PAROXETINE; PROCHLORPERAZINE; PSEUDOEPHEDRINE; QUETIAPINE; RANITIDINE; SELEGILINE; SOLIFENACIN; THIORIDAZINE; TIOTROPIUM BROMIDE; TOLTERODINE; UNINDEXED DRUG; PRESCRIPTION DRUG;

ADULT; AGE; AGED; ANTICHOLINERGIC EFFECT; ANTICHOLINERGIC RISK SCALE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EXPOSURE; FEMALE; GENDER; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SOCIAL ISOLATION; TREND STUDY; VERY ELDERLY; CLINICAL PRACTICE; COMPARATIVE STUDY; INAPPROPRIATE PRESCRIBING; NURSING HOME; RETROSPECTIVE STUDY; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; NURSING HOMES; POLYPHARMACY; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; SCOTLAND; SEX FACTORS; SOCIAL ISOLATION;

EID: 84903188312     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/aft199     Document Type: Article

References (25)

1. Lowry E, Woodman RJ, Soiza RL, Mangoni AA. Associations between the anticholinergic risk scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc 2011; 12: 565-72.
2. Fox C, Richardson K, Maidment ID et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59: 1477-83.
3. Wilson NM, Hilmer SN, March LM et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc 2011; 59: 875-80.
4. Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MGTsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging 2012; 29: 259-73.
5. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JWOuslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195-201.
6. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-13.
7. Remillard AJ. A pharmacoepidemiological evaluation of anticholinergic prescribing patterns in the elderly. Pharmacoepidemiol Drug Saf 1996; 5: 155-64.
8. van Eijk MEC, Avorn J, Porsius AJ, de Boer A. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing. Br Med J 2001; 322: 654-7.
9. Staskin D, Kay G, Tannenbaum C et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc 2010; 58: 1618-9.
10. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60: 616-31.
11. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997; 157: 1531-6.
12. Ryan C, O'Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol 2009; 68: 936-47.
13. Gallagher P, Baeyens JP, Topinkova E et al. Inter-rater reliability of STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment) criteria amongst physicians in six European countries. Age Ageing 2009; 38: 603-6.
14. Stuart B, Kamal-Bahl S, Briesacher B et al. Trends in the prescription of inappropriate drugs for the elderly between 1995 and 1999. Am J Geriatr Pharmacother 2003; 1: 61-74.
15. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ 2011; 342: d3514.
16. Barnett K, McCowan C, Evans JM, Gillespie ND, Davey PG, Fahey T. Prevalence and outcomes of use of potentially inappropriate medicines in older people: cohort study stratified by residence in nursing home or in the community. BMJ Qual Saf 2011; 20: 275-81.
17. Boustani MA, Campbell NL, Munger S, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008; 4: 311-20.
18. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 2006; 46: 1481-6.
19. Hilmer SN, Mager DE, Simonsick EM et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167: 781-7.
20. Botlero R, Davis SR, Urquhart DM, Shortreed S, Bell RJ. Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. Maturitas 2009; 62: 134-9.
21. Nilsson FO, Linner L, Samuelsson E, Milsom I. Costeffectiveness analysis of newer anticholinergic drugs for urinary incontinence versus oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry. BJU Int 2011; 110: 240-6.
22. Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int 2012; 109: 572-80.
23. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing 2012; 42: 62-9.
24. McMurdo ME, Witham MD, Gillespie ND. Including older people in clinical research. BMJ 2005; 331: 1036-7.
25. Gnjidic D, Hilmer SN, Blyth FM et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther 2012; 91: 521-8.